Токсикологическая характеристика дизайнерских наркотиков Medline.ru - медико-биологический информационный портал Медлайн.ру

1. Carroll F.I., Lewin A.H., Mascarella S.W. et al. Designer drugs: a medicinal chemistry perspective // Ann. N Y Acad. Sci. – 2012. – Vol. 1248. – P. 18-38.

2. Постановление Правительства РФ от 29 декабря 2007 г. № 964 «Об утверждении списков сильнодействующих и ядовитых веществ для целей статьи 234 и других статей Уголовного кодекса Российской Федерации, а также крупного размера сильнодействующих веществ для целей статьи 234 Уголовного кодекса Российской Федерации», в ред. от 07 ноября 2013 г.

3. Постановление Правительства РФ от 30 июня 1998 г. № 681 «Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации», в ред. от 09 декабря 2014 г.

4. Федеральный закон от 8 января 1998 г. № 3-ФЗ «О наркотических средствах и психотропных веществах», в ред. от 03 февраля 2015 г.

5. Постановление Правительства РФ от 30 октября 2010 г. № 882 «О внесении изменений в некоторые акты Правительства Российской Федерации по вопросам, связанным с оборотом наркотических средств и психотропных веществ», в ред. от 01 октября 2012 г.

6. Антонов Н.С. Химическое оружие на рубеже двух столетий. – М.: Прогресс, 1994. – 174 с.

7. Мильштейн Г.И., Спивак Л.И. Психотомиметики. – Л.: Медицина, 1971. – 150 с.

8. Шелыгин К.В. Галлюциногенные вещества: классификация, интоксикация, осложнения // Наркология. – 2007. – № 12. – С. 80-90.

9. Херш С. Химическое и биологическое оружие. Тайный арсенал Америки. – М.: Воениздат, 1970. – 208 с.

10. A brief history of methamphetamine – methamphetamine prevention in vermont // URL: http://healthvermont.gov/adap/meth/brief_history.aspx

11. Rasmussen N. Medical science and the military: the Allies\' use of amphetamine during World War II // J. Interdiscip. Hist. – 2011. – Vol. 42, № 2. – P. 205-233.

12. Nelson M.E., Bryant S.M., Aks S.E. Emerging drugs of abuse // Emerg. Med. Clin. North Am. – 2014. – Vol. 32, № 1. – P. 1-28.

13. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones // J. Med. Toxicol. – 2012. – Vol. 8, № 1. – P. 33-42.

14. Шабанов П.Д., Штакельберг О.Ю. Наркомании: патопсихология, клиника, реабилитация. – СПб.: Лань, 2000. – 386 с.

15. Aniline O., Pitts F.N. Jr. Phencyclidine (PCP): a review and perspectives // Crit. Rev. Toxicol. – 1982. – Vol. 10, № 2. – P. 145-177.

16. Ленчик М.В. Пути совершенствования национального законодательства, направленного на противодействие распространению «дизайнерской» наркомании // Вестник Сибирского юридического института ФСКН России. – 2014. – № 4. – С. 53-62.

17. Dean B.V., Stellpflug S.J., Burnett A.M., Engebretsen K.M. 2C or not 2C: phenethylamine designer drug review // J. Med. Toxicol. – 2013. – Vol. 9, № 2. – P. 172-178.

18. Iversen L., White M., Treble R. Designer psychostimulants: Pharmacology and difference // Neuropharmacology. – 2014. – Vol. 87. – P. 59-65.

19. Shulgin A., Shulgin Ann. «Pihkal: A Chemical Love Story». – Berkeley: Transform Press, 1991. – 978 p.

20. Benzenhöfer U., Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin // Addiction. – 2010. – Vol. 105, № 8. – P. 1355-1361.

21. Sreenivasan V.R. Problems in identification of methylenediony and methoxy amphetamines // J. Crim. Law Crim. – 1972. – Vol. 63, № 2. – P. 304-312.

22. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) // URL: http://www.emcdda.europa.eu/

23. United Nations Office On Drugs and Crime (UNODC) // URL: http://www.unodc.org/

24. Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling // Swiss. Med. Wkly. – 2015. – Article 145:w14043. – 12 p.

25. Papaseit E., Farré M., Schifano F., Torrens M. Emerging drugs in Europe // Curr. Opin. Psychiatry. – 2014. – Vol. 27, № 4. – P. 243-250.

26. Brents L.K., Prather P.L. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products // Drug Metab. Rev. – 2014. – Vol. 46, № 1. – P. 72-85.

27. Fantegrossi W.E., Moran J.H., Radominska-Pandya A., Prather P.L. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity? // Life Sci. – 2014. – Vol. 97, № 1. – P. 45-54.

28. EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA // URL: http://www.emcdda.europa.eu/publications/implementation-reports/2013

29. Dresen S., Ferreirós N., Pütz M. et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds // J. Mass Spectrom. – 2010. – Vol. 45, № 10. – P. 1186-1194.

30. Poklis J.L., Amira D., Wise L.E. et al. Detection and disposition of JWH-018 and JWH-073 in mice after exposure to \"Magic Gold\" smoke // Forensic Sci. Int. – 2012. – Vol. 220, № 1-3. – P. 91-96.

31. Schaefer N., Peters B., Bregel D. et al. Can JWH-210 and JWH-122 be detected in adipose tissue four weeks after single oral drug administration to rats? // Biomed. Chromatogr. – 2014. – Vol. 28, № 8. – P. 1043-1047.

32. Chimalakonda K.C., Bratton S.M., Le V.H. et al. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases // Drug Metab. Dispos. – 2011. – Vol. 39, № 10. – P. 1967-1976.

33. Hutter M., Broecker S., Kneisel S., Auwärter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in \'herbal mixtures\' using LC-MS/MS techniques // J. Mass Spectrom. – 2012. – Vol. 47, № 1. – P. 54-65.

34. Sobolevsky T., Prasolov I., Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine // Forensic Sci. Int. – 2010. – Vol. 200, № 1-3. – P. 141-147.

35. Gandhi A.S., Zhu M., Pang S. et al. Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS // Bioanalysis. – 2014. – Vol. 6, № 11. – P. 1471-1485.

36. Strano-Rossi S., Anzillotti L., Dragoni S. et al. Metabolism of JWH-015, JWH-098, JWH-251, and JWH-307 in silico and in vitro: a pilot study for the detection of unknown synthetic cannabinoids metabolites // Anal. Bioanal. Chem. – 2014. – Vol. 406, № 15. – P. 3621-3636.

37. Moran C.L., Le V.H., Chimalakonda K.C. et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine // Anal. Chem. – 2011. – Vol. 83, № 11. – P. 4228-4236.

38. Brents L.K., Reichard E.E., Zimmerman S.M. et al. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity // PLoS One. – 2011. – Vol. 6, № 7. – Article e21917. – 9 p.

39. Головко А.И., Софронов А.Г., Софронов Г.А. \"Новые\" запрещенные каннабиноиды. Нейрохимия и нейробиология // Наркология. – 2010. – № 7. – С. 68-83.

40. Софронов Г.А., Головко А.И., Баринов В.А. и др. Синтетические каннабиноиды. Состояние проблемы // Наркология. – 2012. – № 10. – С. 97-110.

41. Головко А.И., Леонтьева Л.В., Головко С.И. и др. Токсикологическая характеристика синтетических каннабиноидов // Наркология. – 2014. – № 5. – С. 83-93.

42. Seely K.A., Lapoint J., Moran J.H., Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids // Prog. Neuropsychopharmacol. Biol. Psychiatry. – 2012. – Vol. 39, № 2. – P. 234-243.

43. Tomiyama K., Funada M. Cytotoxicity of synthetic cannabinoids found in \"Spice\" products: the role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line // Toxicol. Lett. – 2011. – Vol. 207, № 1. – P. 12-17.

44. Tomiyama K., Funada M. Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death // Toxicol. Appl. Pharmacol. – 2014. – Vol. 274, № 1. – P. 17-23.

45. Vandrey R., Dunn K.E., Fry J.A., Girling E.R. A survey study to characterize use of Spice products (synthetic cannabinoids) // Drug Alcohol Depend. – 2012. – Vol. 120, № 1-3. – P. 238-241.

46. American Association of Poison Control Centers // URL: http://www.aapcc.org/

47. Gugelmann H., Gerona R., Li C. et al. \'Crazy Monkey\' poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid // Clin. Toxicol. (Phila). – 2014. – Vol. 52, № 6. – P. 635-638.

48. Locatelli C.A., Lonati D., Giampreti A. et al. New synthetic cannabinoids intoxications in Italy: clinical identification and analytical confirmation of cases // J. Emerg. Med. – 2011. – Vol. 41, № 2. – P. 220.

49. Müller H., Huttner H.B., Köhrmann M. et al. Panic attack after spice abuse in a patient with ADHD // Pharmacopsychiatry. – 2010. – Vol. 43, № 4. – P. 152-153.

50. Schneir A.B., Cullen J., Ly B.T. \"Spice\" girls: synthetic cannabinoid intoxication // J. Emerg. Med. – 2011. – Vol. 40, № 3. – P. 296-299.

51. Simmons J.R., Skinner C.G., Williams J. et al. Intoxication from smoking \"spice\" // Ann. Emerg. Med. – 2011. – Vol. 57, № 2. – P. 187-188.

52. Van der Veer N., Friday J. Persistent psychosis following the use of Spice // Schizophr. Res. – 2011. – Vol. 130, № 1-3. – P. 285-286.

53. Glennon R.A. Arylalkylamine drugs of abuse: an overview of drug discrimination studies // Pharmacol. Biochem. Behav. – 1999. – Vol. 64, № 2. – P. 251-256.

54. Stellpflug S.J., Kealey S.E., Hegarty C.B., Janis G.C. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): Clinical case with unique confirmatory testing // J. Med. Toxicol. – 2014. – Vol. 10, № 1. – P. 45-50.

55. Eshleman A.J., Forster M.J., Wolfrum K.M. et al. Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function // Psychopharmacology (Berl). – 2014. – Vol. 231, № 5. – P. 875-888.

56. Maurer H.H. Chemistry, pharmacology, and metabolism of emerging drugs of abuse // Ther. Drug Monit. – 2010. – Vol. 32, № 5. – P. 544-549.

57. Meyer M.R., Maurer H.H. Metabolism of designer drugs of abuse: an updated review // Curr. Drug Metab. – 2010. – Vol. 11, № 5. – P. 468-482.

58. Мелентьев А.Б., Катаев С.С. Метаболизм дизайнерских наркотиков. Психоделики серии 2С // Наркология. – 2015. – № 1. – С. 58-68.

59. Carmo H., Hengstler J.G., de Boer D. et al. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human // Toxicology. – 2005. – Vol. 206, № 1. – P. 75-89.

60. Wink C.S., Meyer M.R., Braun T. et al. Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MSn , and LC-high-resolution-MSn // Anal. Bioanal. Chem. – 2015. – Vol. 407, № 3. – P. 831-843.

61. Fantegrossi W.E., Murnane K.S., Reissig C.J. The behavioral pharmacology of hallucinogens // Biochem. Pharmacol. – 2008. – Vol. 75, № 1. – P. 17-33.

62. Nagai F., Nonaka R., Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain // Eur. J. Pharmacol. – 2007. – Vol. 559, № 2-3. – P. 132-137.

63. Murata M., Katagiri N., Ishida K. et al. Effect of β-phenylethylamine on extracellular concentrations of dopamine in the nucleus accumbens and prefrontal cortex // Brain Res. – 2009. – Vol. 1269. – P. 40-46.

64. Nakamura M., Ishii A., Nakahara D. Characterization of β-phenylethylamine-induced monoamine release in rat nucleus accumbens: a microdialysis study // Eur. J. Pharmacol. – 1998. – Vol. 349, № 2-3. – P. 163-169.

65. Halberstadt A.L. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens // Behav. Brain Res. – 2015. – Vol. 277. – P. 99-120.

66. Hill S.L., Thomas S.H. Clinical toxicology of newer recreational drugs // Clin. Toxicol (Phila). – 2011. – Vol. 49, № 8. – P. 705-719.

67. Nichols D.E. Hallucinogens // Pharmacol. Ther. – 2004. – Vol. 101, № 2. – P. 131-181.

68. Meyer M.R., Caspar A., Brandt S.D., Maurer H.H. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches // Anal. Bioanal. Chem. – 2014. – Vol. 406, № 1. – P. 225-237.

69. Kamata T., Katagi M., Tsuchihashi H. Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan // Forensic Toxicol. – 2010. – Vol. 28, № 1. – P. 1-8.

70. Lessin A.W., Long R.F., Parkes M.W. Central stimulant actions of α-alkyl substituted tryptamines in mice // Br. J. Pharmacol. Chemother. – 1965. – Vol. 24. – P. 49-67.

71. Fantegrossi W.E., Reissig C.J., Katz E.B. et al. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents // Pharmacol. Biochem. Behav. – 2008. – Vol. 88, № 3. – P. 358-365.

72. Halberstadt A.L., Geyer M.A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens // Neuropharmacology. – 2011. – Vol. 61, № 3. – P. 364-381.

73. Cozzi N.V., Gopalakrishnan A., Anderson L.L. et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter // J. Neural Transm. – 2009. – Vol. 116, № 12. – P. 1591-1599.

74. Shulgin A., Shulgin Ann. «TIHKAL: The Continuation». – Berkeley: Transform Press, 1997. – 804 p.

75. Gouzoulis-Mayfrank E., Thelen B., Habermeyer E. et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study // Psychopharmacology (Berl). – 1999. – Vol. 142, № 1. – P. 41-50.

76. Gouzoulis-Mayfrank E., Heekeren K., Neukirch A. et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers // Pharmacopsychiatry. – 2005. – Vol. 38, № 6. – P. 301-311.

77. Boland D.M., Andollo W., Hime G.W., Hearn W.L. Fatality due to acute α-methyltryptamine intoxication // J. Anal. Toxicol. – 2005. – Vol. 29, № 5. – P. 394-397.

78. Wilson J.M., McGeorge F., Smolinske S., Meatherall R. A foxy intoxication // Forensic Sci. Int. – 2005. – Vol. 148, № 1. – P. 31-36.

79. Брагин Р.Б. Психиатрический и наркологический аспекты употребления листьев ката: Монография. – Харьков: Пегас, 2010. – 276 c.

80. Watterson L.R., Watterson E., Olive M.F. Abuse liability of novel \'legal high\' designer stimulants: evidence from animal models // Behav. Pharmacol. – 2013. – Vol. 24, № 5-6. – P. 341-355.

81. Shanks K.G., Dahn T., Behonick G., Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry // J. Anal. Toxicol. – 2012. – Vol. 36, № 6. – P. 360-371.

82. Watterson L.R., Olive M.F. Synthetic cathinones and their rewarding and reinforcing effects in rodents // Adv. Neurosci. (Hindawi). – 2014. – Vol. 2014. – Article ID 209875. – 15 p.

83. Glennon R.A. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention // Adv. Pharmacol. – 2014. – Vol. 69. – P. 581-620.

84. Paillet-Loilier M., Cesbron A., Le Boisselier R. et al. Emerging drugs of abuse: current perspectives on substituted cathinones // Subst. Abuse Rehabil. – 2014. – Vol. 5. – P. 37-52.

85. Yeap C.W., Bian C.K., Fahmi A., Abdullah L. A review on benzylpiperazine and trifluoromethylphenypiperazine: origins, effects, prevalence and legal status // Heals environ. J. – 2010. – Vol. 1, № 2. – P. 38-50.

86. Martínez-Clemente J., López-Arnau R., Carbó M. et al. Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics // Psychopharmacology (Berl). – 2013. – Vol. 229, № 2. – P. 295-306.

87. Zaitsu K., Katagi M., Tsuchihashi H., Ishii A. Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: a review of their pharmacology, acute toxicity, and metabolism // Forensic Toxicol. – 2014. – Vol. 32, № 1. – P. 1-8.

88. Zawilska J.B. Mephedrone and other cathinones // Curr. Opin. Psychiatry. – 2014. – Vol. 27, № 4. – P. 256-262.

89. Khreit O.I., Grant M.H., Zhang T. et al. Elucidation of the Phase I and Phase II metabolic pathways of (±)-4′-methylmethcathinone (4-MMC) and (±)-4′-(trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS² // Pharm. Biomed. Anal. – 2013. – Vol. 72. – P. 177-185.

90. Meyer M.R., Wilhelm J., Peters F.T., Maurer H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry // Anal. Bioanal. Chem. – 2010. – Vol. 397, № 3. – P. 1225-1233.

91. Valente M.J., Guedes de Pinho P., de Lourdes Bastos M. et al. Khat and synthetic cathinones: a review // Arch. Toxicol. – 2014. – Vol. 88, № 1. – P. 15-45.

92. Pedersen A.J., Reitzel L.A., Johansen S.S., Linnet K. In vitro metabolism studies on mephedrone and analysis of forensic cases // Drug Test. Anal. – 2013. – Vol. 5, № 6. – P. 430-438.

93. Coppola M., Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as \"bath salts\" or \"plant food\" // Toxicol. Lett. – 2012. – Vol. 211, № 2. – P. 144-149.

94. Shima N., Katagi M., Kamata H. et al. Metabolism of the newly encountered designer drug α-pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites // Forensic Toxicol. – 2014. – Vol. 32, № 1. – P. 59-67.

95. Uralets V., Rana S., Morgan S., Ross W. Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine // J. Anal. Toxicol. – 2014. – Vol. 38, № 5. – P. 233-241.

96. Reith M.E., Blough B.E., Hong W.C. et al. Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter // Drug Alcohol Depend. – 2015. – Vol. 147. – P. 1-19.

97. Baumann M.H., Partilla J.S., Lehner K.R. Psychoactive \"bath salts\": not so soothing // Eur. J. Pharmacol. – 2013. – Vol. 698, № 1-3. – P. 1-5.

98. Pariser J.J., Partilla J.S., Dersch C.M. et al. Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release // J. Pharmacol. Exp. Ther. – 2008. – Vol. 326, № 1. – P. 286-295.

99. Rothman R.B., Dersch C.M., Ananthan S., Partilla J.S. Studies of the biogenic amine transporters. 13. Identification of \"agonist\" and \"antagonist\" allosteric modulators of amphetamine-induced dopamine release // J. Pharmacol. Exp. Ther. – 2009. – Vol. 329, № 2. – P. 718-728.

100. Eiden L.E., Weihe E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse // Ann. N Y Acad. Sci. – 2011. – Vol. 1216. – P. 86-98.

101. Eshleman A.J., Wolfrum K.M., Hatfield M.G. et al. Substituted methcathinones differ in transporter and receptor interactions // Biochem. Pharmacol. – 2013. – Vol. 85, № 12. – P. 1803-1815.

102. Simmler L.D., Buser T.A., Donzelli M. et al. Pharmacological characterization of designer cathinones in vitro // Br. J. Pharmacol. – 2013. – Vol. 168, № 2. – P. 458-470.

103. Fass J.A., Fass A.D., Garcia A.S. Synthetic cathinones (bath salts): legal status and patterns of abuse // Ann. Pharmacother. – 2012. – Vol. 46, № 3. – P. 436-341.

104. Khullar V., Jain A., Sattari M. Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones // J. Gen. Intern. Med. – 2014. – Vol. 29, № 8. – P. 1200-1204.

105. Murphy C.M., Dulaney A.R., Beuhler M.C., Kacinko S. \"Bath salts\" and \"plant food\" products: the experience of one regional US poison center // J. Med. Toxicol. – 2013. – Vol. 9, № 1. – P. 42-48.